<?xml version="1.0" encoding="UTF-8"?>
<ref id="B166-vaccines-08-00224">
 <label>166.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Pontali</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Volpi</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Antonucci</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Castellaneta</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Buzzi</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Tricerri</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Angelelli</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Caorsi</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Feasi</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Calautti</surname>
    <given-names>F.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease</article-title>
  <source>J. Allergy Clin. Immunol.</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1016/j.jaci.2020.05.002</pub-id>
 </element-citation>
</ref>
